Uitgelicht en gespot op internet (week 5, 2023)

Hierbij een nieuwe uitgave van ‘Uitgelicht en gespot op internet‘, een supplement van de ‘Nieuwsbrief voor Goede Onderzoekspraktijken‘, met een overzicht van nieuws en andere berichten die zijn gespot op het internet.

Met vriendelijke groet,

Vincent Bontrop
www.bontrop.com

U kunt met mij linken via LinkedIn en Mastodon.


Accelerating Clinical Trials in the EU (ACT EU), European Medicines Agency (EMA)

Biosimilar medicines

Centrale Commissie Mensgebonden Onderzoek (CCMO), Patiëntenparticipatie

Clinical Research, Clinical Trials

Clinical Trials Regulation (CTR), Clinical Trials Information System (CTIS)

Dutch Oncology Research Platform (DORP)

EudraCT (European Union Drug Regulating Authorities Clinical Trials Database) 

As of 31 January 2023, all initial clinical trial applications in the European Union (EU)/European Economic Area (EEA) must be submitted through the Clinical Trials Information System.

The EudraCT step-by-step guide, the use of the EudraCT database is now limited to:

  • the performance of amendments to EU/EEA Clinical Trial Applications for which the initial submission was done before 31 January 2023
  • the upload of third country files of trials conducted exclusively outside of the EU/EEA that are part of a Paediatric Investigation Plan (PIP) and/or in scope of Article 46 of the Paediatric Regulation (EC) 1901/2006 (so called “third country files”)
  • the update of EudraCT trial statuses by National Competent Authorities
  • the submission of results of EudraCT trials by sponsors

Sponsors must transition their trials to CTIS in case:

  • their EudraCT trial is going to be conducted in additional EU/EEA member state(s), to which a EudraCT CTA was not submitted before 31 January 2023 (this is considered a new trial application for this member state)
  • their EudraCT trial completion date is expected to be after 30 January 2025

In case of a multi-country trial, sponsors should ensure the harmonisation of their clinical trial under the Directive through EudraCT, prior to transitioning their trial to CTIS: see Clinical Trials Regulation Q&A section 11.

bron: EudraCT public home page

European Data Protection Board (EDPB)

European Federation of Pharmaceutical Industries and Associations (EFPIA)

EQUATOR Network

International Pandemic Preparedness Secretariat (IPPS)

Medicines and Healthcare products Regulatory Agency (MHRA)

US Food and Drug Administration (FDA)

ZonMw

Overig


Op de hoogte blijven van actueel nieuws, bijeenkomsten en publieke consultaties

news.bontrop.com events.bontrop.com consultations.bontrop.co